The University of Chicago Header Logo

Connection

Issam Awad to Hemangioma, Cavernous, Central Nervous System

Back to Details
This is a "connection" page, showing publications Issam Awad has written about Hemangioma, Cavernous, Central Nervous System.
Issam Awad
Connection Strength
22.129
Hemangioma, Cavernous, Central Nervous System
  1. Identifying features of prior hemorrhage in cerebral cavernous malformations on quantitative susceptibility maps: a machine learning pilot study. J Neurosurg. 2025 Dec 01; 143(6):1567-1574.
    View in: PubMed
    Score: 0.735
  2. A Systematic Review of MicroRNAs in Hemorrhagic Neurovascular Disease: Cerebral Cavernous Malformations as a Paradigm. Int J Mol Sci. 2025 Apr 17; 26(8).
    View in: PubMed
    Score: 0.724
  3. Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial. Lancet Neurol. 2025 Apr; 24(4):295-304.
    View in: PubMed
    Score: 0.722
  4. Circulating molecules reflect imaging biomarkers of hemorrhage in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2025 Jun; 45(6):1153-1165.
    View in: PubMed
    Score: 0.712
  5. Except for Robust Outliers, Rapamycin Increases Lesion Burden in a Murine Model of Cerebral Cavernous Malformations. Transl Stroke Res. 2025 Jun; 16(3):859-867.
    View in: PubMed
    Score: 0.686
  6. Transcriptomic signatures of individual cell types in cerebral cavernous malformation. Cell Commun Signal. 2024 01 09; 22(1):23.
    View in: PubMed
    Score: 0.663
  7. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling. Stroke. 2024 01; 55(1):31-39.
    View in: PubMed
    Score: 0.661
  8. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome. Stroke. 2024 01; 55(1):22-30.
    View in: PubMed
    Score: 0.661
  9. Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation. J Stroke Cerebrovasc Dis. 2023 Jul; 32(7):107167.
    View in: PubMed
    Score: 0.632
  10. Credulity of exploratory trials for cerebral cavernous malformations. Lancet Neurol. 2023 01; 22(1):2-3.
    View in: PubMed
    Score: 0.612
  11. Propranolol as therapy for cerebral cavernous malformations: a cautionary note. J Transl Med. 2022 04 05; 20(1):160.
    View in: PubMed
    Score: 0.587
  12. Commentary: Feasibility and Morbidity of Magnetic Resonance Imaging-Guided Stereotactic Laser Ablation of Deep Cerebral Cavernous Malformations: A Report of 4 Cases. Neurosurgery. 2021 09 15; 89(4):E207-E208.
    View in: PubMed
    Score: 0.565
  13. COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. J Stroke Cerebrovasc Dis. 2021 Nov; 30(11):106101.
    View in: PubMed
    Score: 0.564
  14. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 02 16; 88(3):686-697.
    View in: PubMed
    Score: 0.542
  15. Propranolol inhibits cavernous vascular malformations by ß1 adrenergic receptor antagonism in animal models. J Clin Invest. 2021 02 01; 131(3).
    View in: PubMed
    Score: 0.541
  16. Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. 2018 02; 9(1):34-43.
    View in: PubMed
    Score: 0.426
  17. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. J Magn Reson Imaging. 2018 04; 47(4):1133-1138.
    View in: PubMed
    Score: 0.425
  18. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 01; 48(1):187-194.
    View in: PubMed
    Score: 0.404
  19. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. J Neurosurg. 2017 Jul; 127(1):102-110.
    View in: PubMed
    Score: 0.396
  20. Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease. J Neurosci Methods. 2016 09 15; 271:14-24.
    View in: PubMed
    Score: 0.393
  21. B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models. J Neuroimmune Pharmacol. 2016 06; 11(2):369-77.
    View in: PubMed
    Score: 0.388
  22. Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. AJNR Am J Neuroradiol. 2016 Jul; 37(7):1209-15.
    View in: PubMed
    Score: 0.385
  23. Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016; 10(3):255-64.
    View in: PubMed
    Score: 0.383
  24. Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2015 Oct; 35(10):1632-9.
    View in: PubMed
    Score: 0.364
  25. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med. 2015 Mar; 17(3):188-196.
    View in: PubMed
    Score: 0.345
  26. Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. J Neuroimmunol. 2014 Jul 15; 272(1-2):67-75.
    View in: PubMed
    Score: 0.339
  27. Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations. Stroke. 2014 Feb; 45(2):598-601.
    View in: PubMed
    Score: 0.329
  28. Cavernous malformations. J Neurosurg. 2012 Jan; 116(1):119-20; discussion 121.
    View in: PubMed
    Score: 0.283
  29. Fatal "hypertensive" intracerebral hemorrhage associated with a cerebral cavernous angioma: case report. Acta Neurochir (Wien). 2011 Feb; 153(2):421-3.
    View in: PubMed
    Score: 0.264
  30. Cerebral cavernous malformations as a disease of vascular permeability: from bench to bedside with caution. Neurosurg Focus. 2010 Sep; 29(3):E4.
    View in: PubMed
    Score: 0.263
  31. Emerging clinical imaging techniques for cerebral cavernous malformations: a systematic review. Neurosurg Focus. 2010 Sep; 29(3):E6.
    View in: PubMed
    Score: 0.263
  32. Advanced magnetic resonance imaging of cerebral cavernous malformations: part I. High-field imaging of excised human lesions. Neurosurgery. 2008 Oct; 63(4):782-9; discussion 789.
    View in: PubMed
    Score: 0.230
  33. Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models. Neurosurgery. 2008 Oct; 63(4):790-7; discussion 797-8.
    View in: PubMed
    Score: 0.230
  34. Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation. J Neurosurg. 2007 Nov; 107(5):1023-6.
    View in: PubMed
    Score: 0.216
  35. Spectrum of genotype and clinical manifestations in cerebral cavernous malformations. Neurosurgery. 2006 Dec; 59(6):1278-84; discussion 1284-5.
    View in: PubMed
    Score: 0.203
  36. Cerebral cavernous malformations: clinical insights from genetic studies. Neurosurg Focus. 2006 Jul 15; 21(1):e1.
    View in: PubMed
    Score: 0.197
  37. Cerebral cavernous malformations and epilepsy. Neurosurg Focus. 2006 Jul 15; 21(1):e7.
    View in: PubMed
    Score: 0.197
  38. Association of Quality of Life Domains and Clinical Symptoms in Patients With Familial Cerebral Cavernous Malformation. J Am Heart Assoc. 2025 Sep 02; 14(17):e035926.
    View in: PubMed
    Score: 0.186
  39. Guidelines for the Diagnosis and Clinical Management of Cavernous Malformations of the Brain and Spinal Cord: Consensus Recommendations Based on a Systematic Literature Review by the Alliance to Cure Cavernous Malformation Clinical Advisory Board Experts Panel. Neurosurgery. 2026 Jan 01; 98(1):3-22.
    View in: PubMed
    Score: 0.182
  40. Intracranial cavernous angioma: a practical review of clinical and biological aspects. Surg Neurol. 2005 Apr; 63(4):319-28; discussion 328.
    View in: PubMed
    Score: 0.180
  41. Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke. 2005 Apr; 36(4):872-4.
    View in: PubMed
    Score: 0.179
  42. Multiple spinal cavernous malformations with atypical phenotype after prior irradiation: case report. Neurosurgery. 2004 Dec; 55(6):1431.
    View in: PubMed
    Score: 0.176
  43. Epigenetic regulation by polycomb repressive complex 1 promotes cerebral cavernous malformations. EMBO Mol Med. 2024 Nov; 16(11):2827-2855.
    View in: PubMed
    Score: 0.175
  44. Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 Signaling. Arterioscler Thromb Vasc Biol. 2024 06; 44(6):1246-1264.
    View in: PubMed
    Score: 0.169
  45. Antithrombotic Therapy in Cerebral Cavernous Malformations: A Systematic Review, Meta-Analysis, and Network Meta-Analysis. J Am Heart Assoc. 2024 Mar 19; 13(6):e032910.
    View in: PubMed
    Score: 0.168
  46. Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations. Nat Commun. 2023 11 02; 14(1):7009.
    View in: PubMed
    Score: 0.164
  47. mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice. Stroke. 2023 11; 54(11):2906-2917.
    View in: PubMed
    Score: 0.162
  48. ß1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations. FASEB J. 2022 12; 36(12):e22629.
    View in: PubMed
    Score: 0.154
  49. Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Transl Stroke Res. 2023 08; 14(4):513-529.
    View in: PubMed
    Score: 0.149
  50. Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project. Stroke. 2021 12; 52(12):3829-3838.
    View in: PubMed
    Score: 0.141
  51. Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation. J Clin Invest. 2021 07 01; 131(13).
    View in: PubMed
    Score: 0.139
  52. Cerebral Cavernous Malformation: From Mechanism to Therapy. Circ Res. 2021 06 25; 129(1):195-215.
    View in: PubMed
    Score: 0.139
  53. Abortive intussusceptive angiogenesis causes multi-cavernous vascular malformations. Elife. 2021 05 20; 10.
    View in: PubMed
    Score: 0.138
  54. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021 06; 594(7862):271-276.
    View in: PubMed
    Score: 0.137
  55. Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. J Exp Med. 2020 10 05; 217(10).
    View in: PubMed
    Score: 0.132
  56. Novel Murine Models of Cerebral Cavernous Malformations. Angiogenesis. 2020 11; 23(4):651-666.
    View in: PubMed
    Score: 0.130
  57. Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. Geroscience. 2020 10; 42(5):1351-1363.
    View in: PubMed
    Score: 0.129
  58. Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. J Autoimmun. 2020 09; 113:102469.
    View in: PubMed
    Score: 0.128
  59. Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2021 03 01; 134(3):1147-1154.
    View in: PubMed
    Score: 0.128
  60. Stereotactic laser interstitial thermal therapy for epilepsy associated with solitary and multiple cerebral cavernous malformations. Neurosurg Focus. 2020 04 01; 48(4):E12.
    View in: PubMed
    Score: 0.128
  61. Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. Int J Mol Sci. 2020 Jan 20; 21(2).
    View in: PubMed
    Score: 0.126
  62. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
    View in: PubMed
    Score: 0.125
  63. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Sci Transl Med. 2019 11 27; 11(520).
    View in: PubMed
    Score: 0.125
  64. Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathol Commun. 2019 08 19; 7(1):132.
    View in: PubMed
    Score: 0.122
  65. A conserved CCM complex promotes apoptosis non-autonomously by regulating zinc homeostasis. Nat Commun. 2019 04 17; 10(1):1791.
    View in: PubMed
    Score: 0.119
  66. Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery. 2019 04 01; 84(4):954-964.
    View in: PubMed
    Score: 0.119
  67. Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease. Stroke. 2019 03; 50(3):738-744.
    View in: PubMed
    Score: 0.118
  68. Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood. 2019 01 17; 133(3):193-204.
    View in: PubMed
    Score: 0.116
  69. The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation. FASEB J. 2019 02; 33(2):2132-2143.
    View in: PubMed
    Score: 0.115
  70. Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest. 2019 03; 99(3):319-330.
    View in: PubMed
    Score: 0.113
  71. Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. 2018 06 08; 122(12):1716-1721.
    View in: PubMed
    Score: 0.112
  72. Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. J Exp Med. 2017 Nov 06; 214(11):3331-3346.
    View in: PubMed
    Score: 0.107
  73. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017 05 18; 545(7654):305-310.
    View in: PubMed
    Score: 0.104
  74. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016 Apr 07; 532(7597):122-6.
    View in: PubMed
    Score: 0.097
  75. Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping. Invest Radiol. 2014 Jul; 49(7):498-504.
    View in: PubMed
    Score: 0.086
  76. Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum Mol Genet. 2014 Aug 15; 23(16):4357-70.
    View in: PubMed
    Score: 0.084
  77. Magnetic resonance imaging evaluation of cerebral cavernous malformations with susceptibility-weighted imaging. Neurosurgery. 2011 Mar; 68(3):641-7; discussion 647-8.
    View in: PubMed
    Score: 0.068
  78. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet. 2011 Jan 15; 20(2):211-22.
    View in: PubMed
    Score: 0.066
  79. Brainstem cavernous malformations. Neurosurgery. 2009 May; 64(5):E805-18; discussion E818.
    View in: PubMed
    Score: 0.060
  80. What genes can teach us about human cerebrovascular malformations. Clin Neurosurg. 2004; 51:140-52.
    View in: PubMed
    Score: 0.041
  81. Ultrastructural pathological features of cerebrovascular malformations: a preliminary report. Neurosurgery. 2000 Jun; 46(6):1454-9.
    View in: PubMed
    Score: 0.032
  82. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010 Apr 12; 207(4):881-96.
    View in: PubMed
    Score: 0.016
  83. Biology of vascular malformations of the brain. Stroke. 2009 Dec; 40(12):e694-702.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.